Second-Line Therapy Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib

Since the era of tyrosine kinase inhibitor (TKI) therapy, there has been an increase in median survival chronic myeloid leukemia. Nevertheless, nowadays were several cases leukemia that are resistant to first-line TKIs, so second-line TKIs introduced. Assessment therapeutic response was performed using a complete peripheral blood examination, bone marrow aspiration cytogenetic and quantitative BCR-ABL examination. The treatment failure criteria applied based on ELN criteria. In selecting second line TKI should be results mutation analysis consider safety profile therapy. This paper will discuss recommendations for therapy TKI, adjusted resources Indonesia.